An Act providing for Commonwealth funding safety and transparency.
Summary
HB461, titled the Commonwealth Funding Safety and Transparency Act, would impose conditions on nonprofit agencies and their subcontractors or service providers that receive Commonwealth funding to promote childbirth and provide alternatives to abortion. The bill prohibits those entities from providing false or misleading information in services or advertising, and requires any advertising paid for with state money to comply with Pennsylvania’s Taxpayer-Funded Advertising Transparency Act.
The bill also adds specific requirements for nonprofit agencies that administer health care-related services such as pregnancy tests, counseling, and postdelivery support. Those providers would have to meet patient safety requirements under the Mcare Act, comply with regulations applicable to certain health care facilities, follow nationally recognized standards from the American Medical Association and the American College of Obstetricians and Gynecologists, and include the full range of FDA-approved contraceptive options in training and materials. Noncompliant organizations would become ineligible for State funding or State tax incentives, and the act would take effect 60 days after enactment.
Impact
HB461 would create new statutory conditions on receipt of Commonwealth funds and state tax incentives by nonprofit pregnancy-support or anti-abortion service providers. It would incorporate by reference existing laws and standards, including the Taxpayer-Funded Advertising Transparency Act, the Mcare Act, the Health Care Facilities Act, and professional guidance from the AMA and ACOG, thereby extending state oversight into advertising, patient safety, service delivery, and educational materials for affected organizations and their subcontractors.
Sentiment
Based on the bill text and the absence of recorded committee debate or votes, the measure appears to be framed by its sponsors as a consumer-protection and transparency bill aimed at ensuring accurate information and safer services. The overall tone of the proposal is regulatory rather than punitive, but it is also closely tied to abortion-related funding and pregnancy-resource organizations, suggesting the bill is likely to draw strong views from both supporters of tighter oversight and opponents who may see it as targeting pro-life service providers.
Contention
The main points of contention are likely to be the bill’s application to nonprofits that promote childbirth and provide alternatives to abortion, and whether the state should condition funding on compliance with medical standards and disclosure rules. Supporters are likely to emphasize truthfulness, patient safety, and transparency in publicly funded services, while opponents may argue that the bill imposes ideological or operational burdens on pregnancy centers, especially through requirements tied to AMA/ACOG standards and mandatory inclusion of contraceptive information.
Providing for pharmaceutical transparency; establishing the Pharmaceutical Transparency Review Board and providing for its powers and duties; establishing the Pharmaceutical Transparency Review Fund; and imposing a penalty.